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Background: A breast cancer susceptibility locus has been mapped to the gene encoding TOX3. Little is known
regarding the expression pattern or biological role of TOX3 in breast cancer or in the mammary gland. Here we
analyzed TOX3 expression in murine and human mammary glands and in molecular subtypes of breast cancer, and
assessed its ability to alter the biology of breast cancer cells.
Methods: We used a cell sorting strategy, followed by quantitative real-time PCR, to study TOX3 gene expression in
the mouse mammary gland. To study the expression of this nuclear protein in human mammary glands and breast
tumors, we generated a rabbit monoclonal antibody specific for human TOX3. In vitro studies were performed on
MCF7, BT474 and MDA-MB-231 cell lines to study the effects of TOX3 modulation on gene expression in the context
of breast cancer cells.
Results: We found TOX3 expression in estrogen receptor-positive mammary epithelial cells, including progenitor
cells. A subset of breast tumors also highly expresses TOX3, with poor outcome associated with high expression of
TOX3 in luminal B breast cancers. We also demonstrate the ability of TOX3 to alter gene expression in MCF7 luminal
breast cancer cells, including cancer relevant genes TFF1 and CXCR4. Knockdown of TOX3 in a luminal B breast
cancer cell line that highly expresses TOX3 is associated with slower growth. Surprisingly, TOX3 is also shown to
regulate TFF1 in an estrogen-independent and tamoxifen-insensitive manner.
Conclusions: These results demonstrate that high expression of this protein likely plays a crucial role in breast
cancer progression. This is in sharp contrast to previous studies that indicated breast cancer susceptibility is
associated with lower expression of TOX3. Together, these results suggest two different roles for TOX3, one in the
initiation of breast cancer, potentially related to expression of TOX3 in mammary epithelial cell progenitors, and
another role for this nuclear protein in the progression of cancer. In addition, these results can begin to shed light
on the reported association of TOX3 expression and breast cancer metastasis to the bone, and point to TOX3 as a
novel regulator of estrogen receptor-mediated gene expression.
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Breast cancer is the second most common cancer in the
US among women, accounting for approximately 40,000
deaths in 2013 [1]. The risk factors contributing to
breast cancer initiation and progression include both
environmental and genetic components, which interact
in a complex and poorly understood fashion. In regard
to the latter, genome wide association studies have been
performed to identify novel disease risk alleles. This
approach has identified high frequency and low pe-
netrance disease-associated single nucleotide polymor-
phisms (SNP) in a number of genes, including that
encoding the HMG-box nuclear protein TOX high mo-
bility group box family member 3 (TOX3) [2,3]. Despite
this association, little is known concerning the expres-
sion pattern or biological functions of TOX3 in breast
cancer or in mammary epithelial cells.
The HMG-box superfamily is defined by a ~80 amino
acid DNA-binding domain, and individual members
function in regulation of gene expression, chromatin
remodeling, genomic stability, DNA repair, and other
DNA-dependent cellular processes (reviewed in ref. [4]).
The thymocyte selection-associated HMG box protein
(TOX) subfamily of HMG-box proteins contains four
evolutionarily conserved proteins: TOX, TOX2, TOX3,
and TOX4. TOX family members share a near identical
DNA-binding domain and are thought to interact with
DNA in a structure-dependent but sequence-independent
fashion [5]. While the N-terminal domains of these pro-
teins share some similarity and have transactivation
activity ([5], and J. Kaye data not shown) the C-terminal
domains are distinct, suggesting the possibility of non-
overlapping functions. The founding member of this
protein family, TOX, plays a key role in the develop-
ment of multiple aspects of the immune system [6-8]
while the in vivo function of TOX3 remains to be
identified.
TOX3 risk-allele carriers have been reported to de-
velop more lobular breast tumors, and patients with this
SNP who develop luminal A (LumA) breast tumors have
shorter overall survival [9]. Rare allele homozygotes were
also found to have a higher risk for distant metasteses
[10], although molecular subtype of the resulting tumors
is uncertain. Recently, Lupien and colleagues [11] used a
bioinformatics approach to identify SNPs directly impli-
cated in increased breast cancer risk. The TOX3 SNP
causative of increased cancer risk is located 18 kb up-
stream of the TOX3 transcription start site. This SNP
alters a FOXA1 binding site, with disease susceptibility
associated with enhanced FOXA1 binding, disrupted
enhancer function, and a decrease in TOX3 gene expres-
sion [11]. This was consistent with earlier work where a
linked disease-associated SNP was correlated with lower
TOX3 mRNA in breast cancers [9,12]. The inverseassociation between TOX3 expression and disease risk
has led to the suggestion that TOX3 may act as a tumor
suppressor [11]. In addition, rare mutations of TOX3 in
breast tumors have been reported [13]. However, some
TOX3 expressing tumors are associated with adverse
outcome [9], and increased expression of TOX3 mRNA
has been implicated in breast cancer metastatic to bone
[14]. Thus, whether TOX3 plays dual and opposing
roles in cancer initiation and progression remains to be
determined.
Here we show that TOX3 is specifically expressed in
the estrogen receptor alpha positive (ER+) subset of
murine mammary luminal epithelial cells, including a
recently identified progenitor cell subset. Using a novel
anti-TOX3 monoclonal antibody developed by our
laboratory, we confirmed high expression of TOX3 in
human breast tissue samples enriched for ER+, proges-
terone receptor positive (PR+), and FOXA1+ luminal
epithelial cells. The TOX3 protein was also highly
expressed in a subset of breast cancers, predominantly
among histologically defined luminal B (LumB) and
LumBHer2+ breast cancer. Since TOX3 overexpression
is associated with poorer outcome in patients with
LumB cancer, we also sought to identify genes whose
expression would be influenced by expression of this
nuclear protein. In the MCF-7 breast cancer cell line,
TOX3 upregulates a subset of ER target genes in
addition to genes involved in cell cycle, cancer progres-
sion and metastasis. The former includes TFF1, which
was upregulated by TOX3 even in the absence of estro-
gen. In addition, TOX3 induces enhancer RNAs that
have been implicated in TFF1 gene regulation. Con-
versely, loss of TOX3 from LumB BT474 breast cancer
cells led to decreased proliferation. Together, this work
implicates a role for TOX3 in tumor progression/metas-
tasis as well as modulation of ER-dependent responses,
potentially explaining the poorer outcome of the TOX3-
high subset of LumB breast cancers. The apparent para-
dox whereby low TOX3 is associated with cancer risk
and high expression is associated with poor outcome is
discussed in relation to TOX3 expression in a subset of
normal mammary epithelial cells.
Methods
Mice
All mice were bred at the Cedars-Sinai Medical Center
and kept under specific pathogen free conditions, or
purchased from the Jackson Laboratory (Bar Harbor,
ME, USA). The CSMC Institutional Animal Care and
Use Committee approved use of animals (IACUC#3376).
Cell culture and transfection
MCF-7, BT474, and MDA-MB-231 cells were generously
provided by Dr. H. Phillip Koeffler (Cedars-Sinai). HEK293T
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Research Institute). Cells were maintained in DMEM
(Life Technologies, Carlsbad, CA, USA) containing 10%
fetal bovine serum (FBS) (Atlanta Biologicals, Flowery
Branch, GA, USA). For experiments involving estrogen
depletion, media was replaced by phenol-free DMEM
(Life Technologies) containing 5% charcoal/dextran-
treated FBS (Atlanta Biologicals).
X-tremeGENE (Roche, Indianapolis, IN, USA) was
used for the transfection of plasmids and Lipofectamine
2000 (Life Technologies) for transfection of siRNAs into
MCF-7 and HEK293T cells. Lipofectamine 2000 was
used for transfection of MDA-MB-231 cells. Two vali-
dated TOX3 or ER Stealth RNAi duplexes and Stealth
RNAi negative control duplexes (Life Technologies) were
tested. Depletion of mRNA expression was measured by
quantitative real-time PCR (qRT-PCR), and the most
efficient RNAi duplex was identified for further use.
RNAi or negative control transfected BT474 cells were
also processed for protein depletion as assessed by
Western blot. The human ESR1 expression plasmid was
purchased from Addgene (Cambridge, MA, USA).
In some experiments, MCF-7 cells were transfected
and after 8 hours switched to estrogen-depleted condi-
tions. After an addiitonal 40 hours of cullture, cells were
assessed for gene expression by qRT-PCR, or GFP+ cells
were sorted for microarray analysis.
The gene encoding the long form of TOX3 was cloned
from a breast cancer sample, sequenced, and compared
with publicly available sequences to rule out mutation.
For stable transfection, MCF-7 cells were transfected
with an IRES-GFP containing empty expression vector
(V) or human TOX3 encoding vector (T). Stable trans-
fectants were selected in 2 mg/ml active G418. Upon
growth, cells expressing equivalent levels of GFP were
isolated from each line by cell sorting. Expression of
TOX3 was confirmed by qRT-PCR and Western blot.
MDA-MB-231 cells were cultured under estrogen-
depleted conditions for 24 hours before transfection. Gene
expression was measured 48 hours after transfection.
Generation and validation of anti-TOX3 monoclonal
antibody
Anti-TOX3 monoclonal antibody was produced in con-
junction with Epitomics (Burlingame, CA, USA). Rabbits
were immunized with a mixture of N- or C-terminal
peptides derived from the long form of TOX3. After
multiple boosting with the peptide mixture, serum was
isolated for analysis. To screen for production of specific
antibodies against the native protein, protein lysates
from HEK293T cells transfected either with empty
vector or a TOX3-encoding expression plasmid were
analyzed by Western dot blot using immune sera.
Hybridomas were then produced from an animal withhigh titer. The resulting antibody-containing culture
supernatants were screened for specific reactivity against
TOX3 transfected HEK293T cells. Based on this analysis,
one clone specific for the N-terminal TOX3 peptide
was chosen for detailed analysis. Anti-TOX3 antibody,
henceforth referred to as AJ-33, was purified by protein
A affinity chromatography and was validated in multiple
assays reported here.
Mammary cell isolation and flow cytometry
All reagents were from StemCell Technologies (Vancouver,
BC, Canada) unless otherwise specified. Mammary
glands from 8–20 week-old virgin female C57Bl/6 mice,
were digested for >8 h at 37°C in EpiCult-B with 5%
FBS, 300U collagenase and 100U hyaluronidase. After
vortexing and lysis of the red blood cells in NH4Cl, a
single cell suspension was obtained by sequential dis-
sociation of the fragments by gentle pipetting for 1–2
minutes in 0.25% trypsin, and then 2 minutes in 5 mg/ml
dispase II plus DNase I followed by filtration through a
40-mm mesh.
Antibodies were obtained from eBioscience/affymetrix
(San Diego, CA, USA). Mouse mammary cells were
preblocked with anti-CD16/CD32 and then incubated
with the following primary antibodies CD31-biotin,
CD45-biotin, Ter119-biotin, BP-1-biotin, EpCAM-AF647,
CD49f-AF488, or CD49f-Pacific Blue, CD49b-PE and
Sca1-PE/Cy7. CD45, Ter119, CD31 and BP-1 were used
to identify contaminating haematopoietic cells, endo-
thelial cells and a proportion of stromal cells, respec-
tively (collectively termed Lin+ cells). Biotin-conjugated
antibodies were detected with streptavidin-APC/Cy7.
Cells were analysed using an LSRII and specific cell popu-
lations isolated using a FACSAria III (BD Biosciences,
San Jose, CA, USA). Flow cytometry data were ana-
lysed using FlowJo™ software (Tree Star, Ashland,
OR, USA).
For surface CXCR4 detection, 5 × 105 cells were incu-
bated at 4°C for 45 min with 5 μg/ml of the specific
monoclonal antibody to CXCR4 conjugated to PE. Cells
were washed twice with PBS and resuspended in 500 μL
of PBS for analysis.
Boyden chamber migration assay
For migration studies, cells were first grown in phenol
red- and serum-free DMEM for 24–48 hours. Subse-
quently, 2 × 105 cells were seeded in 500 μl serum-free
DMEM in the upper chamber of a 24 well transwell
system (ThermoFisher Scientific, Waltham, MA, USA).
Phenol red-free DMEM supplemented with 10% char-
coal stripped dextran treated FBS was used as a chemo-
attractant in the lower wells. Phenol red- and serum-free
DMEM was used as a negative control to assess basal
migration rates. After 24 hours, membranes were scrubbed
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removed and stained using Diffquik (ThermoFisher
Scientific). Migrated cells were visualized by microscopy
and the number of cells in the center of each well was
counted. Data are represented as number of migrated cells
per field of view ± SD for triplicate samples.
Cell proliferation
Cells were seeded in 24-well plates (1 × 104 cells per
well) and cultured for 10 days (MCF-7) or 14 days
(BT474) in appropriate culture medium. Numbers of
viable cells were determined using Trypan Blue (Sigma-
Aldrich, St. Louis, MO, USA).
qRT-PCR
Primary breast cancer RNA samples were purchased
from BioServe (Beltsville, MD, USA). Otherwise, RNA
extraction was performed using the RNAeasy kit
followed by cDNA production using the Quantitect Re-
verse Transcription kit (Qiagen, Valencia, CA, USA).
qRT-PCR was performed using SYBR Green PCR Master
Mix and commercially available primers (Qiagen) were
used unless indicated. GAPDH, MRPL, or ACTB expres-
sion served as housekeeping gene controls. Relative gene
expression was analyzed using the 2-ΔΔCt method. Pri-
mer sequences to detect TOX3 variants are available
upon request. For pre-mRNA measurements, RNA was
isolated and qRT-PCR performed as above, but using
primers that specifically detect pre-spliced TFF1 mRNA
as previously described [15].
Nuclear extractions and Western blot
Nuclear protein was isolated using a Nuclear Extract Kit
(Active Motif, Carlsbad, CA, USA). 20 μg of protein
lysate was subjected to Western blotting using AJ-33 or
anti-Actin (EMD Millipore, Billerica, MA, USA) anti-
bodies as detected by peroxidase-conjugated anti-rabbit
IgG antibody (Bio-Rad, Hercules, CA, USA) and
chemiluminescence.
Immunofluorescence
HEK293T cells were grown on eight-well chamber slides.
After 48 hours of transfection, cells were fixed in 4%
paraformaldehyde, blocked in 10% normal goat serum
for 1 hour, and stained with primary antibodies over-
night at 4°C. Goat anti-rabbit antibody conjugated to PE
(Jackson ImmunoResearch Laboratories, West Grove,
PA, USA) was used to detect primary antibodies. Slides
were mounted with 4',6-diamidino-2-phenylindole (DAPI)
(Life Technologies) to visualize nuclei.
Tissue samples and immunohistochemistry
Immunohistochemical detection of TOX3 was performed
on 4-μm sections of formalin fixed paraffin embeddedtissue stained with AJ-33. Staining was done using an
automated slide stainer (Dako, Carpinteria, California,
USA). Antigen retrieval was performed using the Dako PT
Link Module and low pH buffer. Staining was visualized
using the Dako Envision + Rabbit Detection System.
Slides were subsequently counterstained with Mayer’s
hematoxylin (Sigma-Aldrich). Three commercially avail-
able tissue arrays (Pantomics, Richmond, CA, USA) that
contained a total of 210 primary breast cancer samples
in duplicate were analyzed for TOX3 expression. Some
samples were destroyed during the processing and
therefore removed from analysis. Thus, the TOX3 histo-
logical data shown here are derived from a total of 188
breast tumors. Other histological data that were asso-
ciated with individual tumors on the tissue array were
supplied by the manufacturer. For some histological
analysis, the Department of Pathology and Laboratory
Medicine at CSMC supplied normal breast tissue ob-
tained following mammoplasty. Samples were obtained
under a waiver of consent and provided in an anony-
mous fashion, so that the connection to individual pa-
tients was destroyed prior to their analysis. This work
was performed under Cedars-Sinai Medical Center’s
Institutional Review Board Study Number: Pro 00033387.
Molecular subtyping and microarray analysis
Publicly available (GSE12093, GSE11121, GSE7390,
GSE2034) breast cancer microarray expression data was
compiled and normalized using 820 patient samples run
only on Affymetrix (Santa Clara, CA, USA) gene chips.
Samples were molecularly subtyped using the CIT classifi-
cation algorithm R package provided by the authors [16].
Multiple probes of the TOX3 gene were averaged. A box-
and-whisker plot was generated demonstrating the levels of
TOX3 mRNA expression within each molecular subtype.
Human gene expression analysis was performed using
Affymetrix microarrays. In brief, RNA was isolated using
the RNAeasy kit (Qiagen), and RNA quality was assessed
using a Nanodrop (Thermo Scientific, Wilmington, DE,
USA) spectrometer and an Agilent 2100 Bioanalyzer.
RNA was reverse transcribed and hybridized to HuGene
1.0 Affymetrix arrays and processed according to manu-
facturer’s recommendations. Data were normalized using
Justplier algorithm by Affymetrix available in Bioconduc-
tor v2.0 and R v.3.0. Since microarray signals are not
quantitative at lower and higher values, signal thresholds
for floor and ceiling were set for all samples. Two-way
unsupervised hierarchical clustering was performed to
assess unbiased gene expression patterns associated with
samples. Genes whose intensity varied at least two fold
between any two arrays independent of treatment were
analyzed. Dendrograms were then constructed from a
distance matrix containing Pearson correlations calculated
iteratively between the four samples and 223 genes.
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Two-tailed Student t tests were used for significance tes-
ting; P < 0.05 was considered significant with * = P <0.05,
** = P <0.01, and *** = P <0.001. Error bars represent
standard deviation of replicates.
Availability of supporting data
Raw binary CEL files as well as normalized data for
microarray analysis were deposited in Gene Expression
Omnibus at NCBI (http://www.ncbi.nlm.nih.gov/geo/)
and can be obtained using Accession # GSE57856.
Results
TOX3 expression in mouse and human breast epithelium
TOX3 expression has not been well defined in normal
mammary epithelial cells. Indeed, TOX3 was reported to
be poorly expressed in total breast tissue [17]. We utilized
previously identified subsets of murine mammary epithelial
cells [18] to analyze Tox3 expression in isolated basal epi-
thelial cells (CD49f+EpCAMlow), ER− luminal progenitor
cells (CD49f+EPCAMlowCD49b+Sca1−), ER+ luminal pro-
genitor cells (CD49f+EpCAMlowCD49b+Sca1+), and ER+
mature luminal cells (CD49f+EPCAMlowCD49b−Sca1+)
(Figure 1A). Tox3 was not detectable in basal cells, and
minimally expressed in ER− luminal progenitor cells
(Figure 1B). In contrast, there was higher expression of
Tox3 mRNA in ER+ progenitors and ER+ mature luminal
cells (Figure 1B). The transcriptome of human counter-
parts of these cell populations has recently been reported
[18]. Analysis of this expression data demonstrated a simi-
lar pattern of TOX3 expression, with highest levels of
TOX3 in ER+ luminal progenitors and ER+ mature luminal
cells (Additional file 1: Figure S1).
To further characterize TOX3 expression in human
mammary epithelium at the protein level, we produced a
rabbit anti-human TOX3 monoclonal antibody (AJ-33).
To test for specificity, we transfected HEK293T cells
with a CMV promoter-based vector expressing TOX3
and GFP, the latter under control of an IRES. Trans-
fected cells were mixed at various ratios with non-
transfected cells and a Western blot was performed
using AJ-33 (Additional file 2: Figure S2A). A single
band of apparent molecular weight (MW) of ~65 kDa was
detected in a quantitative manner only in transfected cells,
correlating with qRT-PCR results (Additional file 2:
Figure S2A). To determine subcellular localization of
TOX3, we performed confocal microscopy on TOX3
transfected cells, using empty vector (GFP alone) trans-
fected cells as a control. TOX3, like TOX [5], contains
a putative bipartite nuclear localization signal adjacent
to the HMG-box. Consistent with this, TOX3 expres-
sion as determined by AJ-33 staining was localized to
the nucleus in transfected cells (Additional file 2:
Figure S2B). This antibody was then used to studyprotein expression of TOX3 in human mammary
epithelium.
Formalin-fixed paraffin-embedded sections of ten
mammoplasty breast samples were immunostained with
AJ-33. Variable TOX3 expression was observed in mam-
mary epithelium, with some areas exhibiting no TOX3+
cells and in other areas showing a high proportion of
TOX3+ cells (Figure 1C). As in transfected cells, TOX3
staining was confined to the cell nucleus. TOX3 protein
was detected solely in luminal epithelial cells; no staining
was observed in stromal or myoepithelial cells, consist-
ent with the absence of TOX3 gene expression in murine
and human basal epithelial cell populations noted above.
As TOX3 mRNA was primarily detected in ER+ lu-
minal epithelial cells, we asked whether TOX3 protein
expression was associated with this cell subset in human
mammary gland tissue. Serial sections demonstrated that
areas of mammary tissue with a high proportion of
TOX3hi cells also expressed ER, the ER target progester-
one receptor (PR), and the ER pioneer factor FOXA1
(Figure 1D,E). Interestingly, these same areas had a very
high proportion of ER+ luminal cells. However, not all
areas with a high proportion of ER+ luminal cells were
TOX3+ (data not shown).
TOX3 is expressed in a subset of breast cancer and
correlates with poor outcome
Analysis of a series of samples from primary breast can-
cer revealed extreme variability in TOX3 mRNA expres-
sion ranging from undetectable to 100-fold over that
detected in two normal breast tissue samples (Figure 2A).
Two TOX3 splice variants predicted to encode proteins
with distinct N-terminal sequences (NP_001073899.2 and
NP_001139660.1) have also been reported (Figure 2B).
However, nothing is known about the expression of these
isoforms in normal tissue or breast cancer. Using a com-
mon downstream primer and specific upstream primers
that allowed us to distinguish these variants by PCR, the
long form of TOX3 appears as the predominant mRNA in
breast cancer cell lines and two primary breast tumors
(Figure 2B). As expected, lower levels of TOX3 were found
in total normal breast tissue, with only the long form
detected in these samples (Figure 2B).
Breast cancer is a heterogeneous disease and various
attempts have been made to define molecular subtypes
with prognostic value. To determine if the expression of
TOX3 was associated with a particular molecular sub-
type of breast cancer, we analyzed a publicly available
microarray data set of primary human breast cancers.
Tumors were classified into six intrinsic molecular sub-
types, LumA, LumB, luminal C, basal, normal-like and
molecular apocrine, as previously reported [16]. TOX3
was expressed across multiple molecular subtypes, in-
cluding luminal, molecular apocrine, and normal-like
Figure 1 TOX3 is expressed in mouse and human mammary epithelium. A. Gating strategy used to sort mouse mammary epithelial cell
populations is shown. Contour plot on the right is gated on the luminal epithelial population as shown. B. qRT-PCR for mouse Tox3 in the indicated
sorted cell populations. Data are expressed as mean ± SD of three independent sorts. C. Immunohistochemical staining of TOX3 in reduction
mammoplasty samples showing areas of high and low TOX3 protein expression within an individual (magnification, 40X). D. Immunohistochemical
staining of serial sections with antibodies specific for TOX3, ER, and PR (magnification 20X). E. Immunohistochemical staining of serial sections for TOX3
and FOXA1 at indicated magnification. Examples of FOXA1+ and FOXA1− nuclei are indicated by red and green arrows, respectively.
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expressed TOX3 (Figure 2C), consistent with a previous
report [19].
To assess expression of the TOX3 protein in breast tu-
mors, we stained a tissue array with AJ-33 antibody.
TOX3 protein expression ranged from undetectable to
highly expressed, both in frequency of cells stained and
intensity of staining (Figure 3A and data not shown),
mirroring the high variability in TOX3 mRNA found in
tumor samples (Figure 2A). TOX3 expression was local-
ized to the tumor cell nucleus, and was not detected insurrounding stroma. Using a threshold of >10% of stained
epithelial cells, ~15% of the cancers expressed TOX3. We
further classified tumors on the array as LumA (ER+Her2−,
Ki67 < 14%), LumB (ER+Her2−, Ki67 ≥ 14%), LumBHer2,
(ER+Her2+, Ki67 ≥ 14%), Her2 (ER−Her2+), and triple
negative (ER−PR−Her2−), based on accompanying histo-
logical data. In contrast to the microarray data, LumB and
LumBHer2 tumors showed clear enrichment for TOX3
expression compared to other subtypes (Figure 3B).
This may reflect differences in molecular compared to
histological subtyping, discordance between mRNA and
Figure 2 TOX3 mRNA is expressed in multiple molecular subtypes of breast cancer. A. Expression of TOX3 was determined by qRT-PCR in
breast cancer (red) and normal breast (blue) samples, relative to housekeeping gene MRPL. Relative expression was then normalized to ‘Normal 1’.
B. RT-PCR analysis of the long (Var1) and short (Var2) variants of TOX3, and GAPDH, in breast cancer cell lines (BT474, MCF-7), two normal breast samples,
and two primary breast cancer samples BC6 and BC1, as in (A). C. Relative TOX3 mRNA expression in six intrinsic molecular subtypes of breast cancer.
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in cell lines, data not shown), or the quantitative limita-
tions of array-based transcriptome analysis, emphasi-
zing the importance of protein expression analysis.Since a substantial subset of LumB breast tumors highly
expressed TOX3, we sought to correlate TOX3 expres-
sion with outcome, using the on-line KM-Plotter for
breast cancer [20]. Patients with LumB tumors were
Figure 3 TOX3 is highly expressed in a subset of LumB tumors and is associated with poor prognosis. A. Examples of TOX3 protein
expression in six primary breast cancer samples. B. Proportion of TOX3hi (red) tumors among histologically defined breast cancer subtypes on
tissue array of 188 breast tumors. C. Kaplan-Meier plots showing overall survival (OS) and recurrence free survival (RFS) of patients bearing TOX3hi
tumors of the LumB and LumA subtypes. Hazard ratios, confidence intervals, and logrank P values are shown.
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expression of TOX3 mRNA expression was associated
with a highly significant decrease in overall and recur-
rence free survival (Figure 3C). Most interestingly, no
such association was seen among patients with LumA
tumors (Figure 3C).
TOX3 regulates genes involved in breast cancer
aggressiveness in MCF-7 cells
MCF-7 is an ER+ luminal type breast cancer cell line with
low TOX3 expression (Figure 2B). To determine the effects
of TOX3 on gene expression, we performed transient trans-
fection of these cells with an expression vector encoding
the predominant form of TOX3 in conjunction with GFP
or, as a control, GFP alone. Vector control or TOX3-trans-
fected cells expressing equivalent levels of GFP wereFigure 4 Expression of TOX3 in MCF-7 cells leads to upregulation of g
clustering of gene expression changes in MCF-7 cells upon transient expre
result. Data are expressed as mean ± SD of three independent experiments. C
D. Cell survival of stably transfected MCF-7 cell lines at indicated days, grown
cultures. E. BT474 cell growth upon siRNA-mediated knockdown of TOX3. Datisolated by cell sorting and subjected to whole transcrip-
tome microarray analysis. As previous data suggested that
TOX3 could regulate gene expression from promoters
carrying an estrogen response element [17], these experi-
ments were carried out under estrogen-depleted condi-
tions. Unsupervised hierarchical clustering of independent
biological replicates suggests that TOX3-expressing MCF-
7 had coordinated gene expression changes that were dis-
tinct from vector controls (Figure 4A, Additional file 3:
Figure S3). In this context, TOX3 acted primarily as a
transcriptional activator, with expression of the protein
upregulating a large number of genes and downregulating
a much smaller subset of genes, although we can not dis-
tinguish direct from indirect gene targets (Figure 4A).
The ability of TOX3 to upregulate a number of genes im-
plicated in breast cancer or mammary gland development,enes implicated in cancer progression. A. Two-way hierarchical
ssion of TOX3. B. qRT-PCR validation of selected genes from microarray
. TOX3 mRNA and protein expression (inset) in MCF-7 stable cell lines.
in estrogen-depleted medium. Data are expressed as mean ± SD of three
a are expressed as mean ± SD of five independent experiments.
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was confirmed by qRT-PCR in transiently transfected
cells under estrogen-depleted conditions (Figure 4B).
We also subjected these microarray data to Ingenuity
pathway analysis (Additional file 4: Figure S4). Upregu-
lation of multiple members of gene networks involved
in cell cycle, DNA repair, and cancer was observed,
including upregulation of BRCA1 and 2, and BIRC5
(Survivin) genes.
To study the biological consequences of TOX3 over
expression, two independent MCF-7 cell lines were
generated and mRNA and protein analyses confirmed
expression of TOX3 (Figure 4C). Given that MCF-7 cells
are highly dependent on estrogen for growth and sur-
vival and that TOX3 could upregulate genes important
for cell cycle, we estrogen-depleted the stably transfected
cells and monitored their growth. Although TOX3 did
not promote cell proliferation in the absence of estrogen,
we observed significantly more cells in TOX3 expressing
cell cultures at day 10 relative to vector control cells, sug-
gesting some resistance to estrogen depletion (Figure 4D).
These results suggested that TOX3 might play a role in
enhancing tumor cell proliferation and/or survival. To
address this, we performed siRNA-mediated knock-
down of TOX3 in BT474 cells. BT474 is a LumB cell
line [25] that highly expresses TOX3 (Figure 2B), con-
sistent with expression of TOX3 protein in a significant
proportion of primary LumB tumors as described above.
Decrease in TOX3 expression significantly inhibited
BT474 expansion over a 12-day period (Figure 4E).
TOX3 promotes migration of MCF-7 cells and is
upregulated by IGF-1
Among the genes upregulated by TOX3 in our micro-
array analysis (Figure 4a) was the well-studied pro-
metastatic gene CXCR4 [26-28]. To determine if cells
stably expressing TOX3 also maintained expression of
this chemokine receptor at the level of RNA and protein,
we performed qRT-PCR and FACS analysis, respectively.
Both analyses demonstrated upregulation of CXCR4 in
cells that expressed TOX3 as compared to vector con-
trol cell lines (Figure 5A, B). Interestingly, cell surface
expression of CXCR4 was limited to a subset of TOX3+
(GFP+) cells (Figure 5B). Given the change in chemokine
receptor expression, we asked whether TOX3 expression
could influence cell migratory properties. We observed
increased migration of cell lines expressing TOX3 in
response to serum (Figure 5C, D).
Recently, it has been demonstrated that IGF-1 coope-
rates with CXCR4 signaling to promote bone marrow
metastasis of breast cancer, potentially one factor in the
aggressive behavior of LumB tumors [29]. Given that
TOX3 upregulated CXCR4, enhanced the migratory
properties of MCF-7 cells, and is highly expressed inLumB tumors, we asked whether IGF-1 could play a role
in regulating TOX3 expression. Indeed, MCF-7 cells
treated with IGF-1 showed significant, albeit modest,
upregulation of TOX3 expression (Figure 5E), as well as
the known IGF-1 target gene GAPDH [30]. Together,
these results offer a potential link between breast cancer
metastasis and TOX3 expression.
TOX3 regulates estrogen responsive genes in a
ligand-independent manner
Approximately 27% of the genes whose expression was
modulated by TOX3 in the above analysis have been pre-
viously reported to be regulated by estrogen in MCF-7
cells ([31] (Figure 6A). Given this, we were surprised that
the well-characterized estrogen responsive gene TFF1
[32,33] did not meet our stringent microarray threshold
criteria. However, upon closer inspection this was due to
variable basal expression of TFF1 in the estrogen-starved
cells used in the microarray experiment. Using qRT-PCR,
however, we observed a significant and consistent up-
regulation of TFF1 by TOX3 in estrogen depleted MCF-7
(Figure 6B). Consistent with the results from these tran-
sient transfections, two stably transfected independent
MCF-7 cell lines that expressed TOX3 maintained higher
TFF1 expression in the absence of estrogen when
compared to vector-transfected control MCF-7 cell lines
(Figure 6C). To more accurately gauge whether TFF1 was
actively transcribed in the absence of estrogen, we
analyzed TFF1 pre-mRNA following 48 hours of estrogen
depletion. As expected,TFF1 pre-mRNA is induced by es-
trogen in vector transfected control cell lines (Figure 6D).
In contrast, TFF1 pre-mRNA is upregulated in TOX3
overexpressing cells compared to control cells even in the
absence of estrogen (vehicle treated), and induced to very
high levels in the presence of estrogen (Figure 6D). This
suggests that the TFF1 gene is not only upregulated by
TOX3 in the absence of estrogen, but that TOX3 can en-
hance the estrogen responsiveness of this gene.
ER binding sites are found in the TFF1 promoter and
in two upstream enhancer regions, and ER is thought to
be involved in looping of the chromatin to juxtapose
enhancers and promoter [34,35]. Recently, long non-
coding enhancer RNAs (eRNA) have been shown to play
a key role in the estrogen-mediated upregulation of
TFF1 in MCF-7 cells [36]. Treatment of MCF-7 cells
with estrogen upregulated both of the reported TFF1
eRNAs (transcribed from different strands) (Figure 6E).
Interestingly, these same eRNAs were upregulated in
TOX3 expressing MCF7 cells in the absence of estrogen
(Figure 6E). Addition of estrogen to TOX3-expressing
cells further upregulated eRNA1 (Figure 6E). A trend
towards further upregulation of eRNA2 was seen in the
presence of estrogen in TOX3-expressing cells, although
this did not reach significance and was of lower
Figure 5 TOX3 enhances MCF-7 migration and is upregulated by IGF-1. A. qRT-PCR and B. FACS analysis, for CXCR4 expression in two
independently generated vector or TOX3 stably transfected MCF-7 cell lines. C. Representative images of migratory cells in vector control (V) or
TOX3-expressing (TOX3) cell lines. D. Quantification of migratory cells in vector and TOX3 transfected cell lines using FBS as chemo-attractant.
Data are expressed as mean ± SD of three independent experiments. E. qRT-PCR analysis of TOX3 and GAPDH (a positive control for IGF-1 response),
relative to ACTB, in MCF-7 cells treated with IGF-1. Data are expressed as mean ± SD of three independent experiments.
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gest that TOX3 can differentially regulate these two
eRNAs.
Given these results, we asked whether TOX3 is
involved in endogenous regulation of TFF1 expres-
sion in MCF-7 cells, despite low to undetectableexpression of the protein in this cell line (Figure 4C).
siRNA-mediated knockdown of TOX3 blunted the
TFF1 response to estrogen treatment in MCF-7 cells
(Figure 6F), suggesting that even low levels of
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Figure 6 TOX3 regulates estrogen-responsive genes in a ligand-independent manner. A. Overlap of genes upregulated by TOX3 (yellow)
in MCF-7 cells as shown here, and those previously reported to be bound by ER and/or be regulated by estrogen [31] (blue). B. TFF1 mRNA
expression in transiently transfected MCF-7 cells under estrogen depleted conditions. Data are expressed as mean ± SD of three independent
experiments. C. TFF1 gene expression in stably transfected MCF-7 cell lines. D. TFF1 pre-mRNA expression in indicated cell lines treated with
estrogen (E2) or vehicle (EtOH). E. eRNA expression in stably transfected MCF-7 cells. Data are expressed as mean ± SD of three independent
experiments. F. Estrogen-induced TFF1 mRNA expression following siRNA-mediated TOX3 knockdown as indicated. Data are expressed as mean ±
SD of six independent experiments. G. TFF1 expression following siRNA mediated ER knockdown in MCF-7 stable cells lines as indicated in
presence of estrogen (E2) or vehicle (EtOH). Data are expressed as mean ± SD of four independent experiments. H. TFF1 expression after ER
and/or TOX3 transfection of MDA-MB-231 cells and with indicated additions. Data are expressed as mean ± SD of four independent experiments.
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estrogen, we asked if ER was required for TOX3 regula-
tion of TFF1 gene expression. As expected, siRNA-
mediated knockdown of ER inhibited estrogen mediated
TFF1 induction in MCF-7 (Figure 4G). Surprisingly,
however, loss of ER did not affect TFF1 expression in
TOX3 stably expressing cells in the absence of estrogen
(Figure 6G). In contrast, ER was required for estrogen up-
regulation of TFF1 in TOX3-expressing cells (Figure 6G).Together, these data suggest that stable maintenance of
TFF1 expression in the presence of TOX3 and absence of
estrogen is largely ER independent.
To address whether the induction of TFF1 by TOX3
was ER-dependent, we transfected triple negative basal
MDA-MB-231 breast cancer cells, which do not express
ER or TOX3. Neither expression of TOX3 nor ER alone
induced TFF1 in MDA-MB-231 cells (Figure 6H). How-
ever, expression of both TOX3 and ER led to TFF1
Seksenyan et al. BMC Cancer  (2015) 15:22 Page 13 of 16induction (Figure 6H). Moreover, cells expressing TOX3
and ER were more responsive to estrogen than cells ex-
pressing ER alone (Figure 6H).
Discussion
We show here that murine Tox3 is highly expressed in
ER+ luminal progenitors and ER+ mature luminal cells,
but not in ER− luminal progenitors or basal epithelial
cell populations. Taking advantage of the recently re-
ported expression profiling of the human counterparts
of these cells, we found a similar expression pattern in
the human mammary gland.
The function of TOX3 in the mammary epithelium re-
mains to be determined. However, that TOX3 has the
potential to regulate a subset of ER target genes (see
below) raises the possibility that TOX3 might play a
similar role in normal mammary epithelium. Interest-
ingly, ER+ progenitors have been shown to be resistant
to in vivo estrogen deprivation [18]. Given our results of
ligand-independent estrogen target gene upregulation by
TOX3 in tumor cells, it is possible that TOX3 also con-
tributes to the relative insensitivity of these progenitors
to estrogen deprivation.
Two TOX3 transcripts encoding proteins with distinct
N-termini have been reported, and we found predomi-
nant expression of mRNA encoding the long form of
TOX3 in normal breast tissue, breast cancer cell lines,
and primary breast cancer. Using a rabbit anti-TOX3
monoclonal antibody specific for the long-form of the
protein, we showed that TOX3 is exclusively a nuclear
protein that is expressed in a subset of luminal epithelial
cells, but not in myoepithelial cells or stroma, consistent
with the expression pattern of the gene. Expression of
TOX3 protein was not uniform, and areas exhibiting
high levels of expression were seen in luminal epithelial
cells in some samples. Areas enriched for TOX3-
expressing cells were also highly enriched for epithelial
cells expressing ER, PR, and FOXA1. Whether these
TOX3+ islands represent ER+ progenitors and/or an ER+
subset of mature epithelial cells is not known. TOX3
expression was not associated with highly proliferative
regions of the mammary gland as assessed by Ki67 stai-
ning (data not shown).
The coexpression of TOX3 and FOXA1 in a subset of
luminal epithelial cells is interesting. The expression of
TOX3 is regulated at least in part by FOXA1, an ER pi-
oneer factor that is involved in delineating the luminal
lineage [37-39]. FOXA1 is thought to be a positive regu-
lator of TOX3 expression, mediated by binding to an up-
stream enhancer [11], and knockdown of FOXA1 in a
breast cancer cell line decreased TOX3 expression [40].
We also observed modest TOX3 upregulation in MCF-7
cells following IGF-1 treatment. This growth factor has
been shown to contribute to breast cancer progressionand endocrine resistance [29,41] through stabilization of
FOXA1 protein in MCF-7 cells [42]. Moreover, FOXA1
alters the pattern of ER binding in ‘poor outcome/meta-
static’ ER+ breast cancer from that found in ER+ ‘good
outcome’ breast cancer [43]. Identification of genes
within 20 kb of these differential ER binding sites led to
a gene expression predictor set that included TOX3, with
upregulation of TOX3 associated with poor outcome pa-
tients. In normal cells, a FOXA1-TOX3 circuit may play
a role during progenitor cell differentiation of the ER+
luminal cell subset. However, the disease risk allele SNP
increases the affinity of FOXA1 for the TOX3 upstream
enhancer, inhibiting the function of this regulatory se-
quence and leading to a reduction in TOX3 expression
[11]. This suggests additional complexity in TOX3 gene
regulation, where a narrow range of FOXA1 binding
may be key to appropriate enhancer function.
The TOX3 gene was expressed across multiple mo-
lecular subtypes of breast cancers, and there was hetero-
geneity of expression within each subtype. The notable
exception was basal tumors, which were generally
TOX3-/low. The TOX3 protein was expressed in a signifi-
cant proportion of histologically defined LumB tumors,
and high expression of the TOX3 gene in patients bear-
ing LumB tumors was associated with poorer outcome.
Expression profiling comparisons between LumB tumors
and normal mammary epithelial cell population has sug-
gested that these tumors are most similar to ER+ luminal
progenitors and ER+ mature luminal cells [18,25], the
two cell populations that normally express TOX3. Thus,
ER+ luminal progenitors may be one origin of TOX3+
LumB tumors.
MCF-7 cells poorly express endogenous TOX3 pro-
tein. This is likely due to heterozygosity for the TOX3
SNP affecting enhancer function [11]. Using MCF-7
cells, we found that TOX3 has the ability to acutely
regulate key genes involved in cell cycle and metastases,
two key features in breast cancer progression. Consistent
with a role for TOX3 in proliferation of tumor cells,
knockdown of TOX3 in BT474 inhibits growth in cul-
ture, while knockdown of TOX3 in ZR-75-1 led to poor
tumor formation in nude mice [44].
We also found upregulation of CXCR4 and an increase
in migration of TOX3-expressing MCF-7 cells. In con-
junction with upregulation of TFF1, this may partly ex-
plain the finding that primary breast cancers that
subsequently metastasize specifically to the bone are as-
sociated with upregulation of TOX3 (TNRC9 in [14]).
Although TOX3 expression led to consistent upregula-
tion of CXCR4 at the cell population level, expression of
this chemokine receptor was only evident on a subset of
cells that expressed TOX3 (Figure 6B and data not
shown). This may reflect the intrinsic stochastic nature
of gene regulation [45,46], and raises the possibility that
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sequence specific fashion to modify chromatin [5], may
alter the threshold of gene regulation and result in
tumor cell heterogeneity that can then be acted upon by
selective pressures.
The disease associated TOX3 SNP has been shown to
have an additive effect on disease risk in BRCA1 mutation
carriers [47]. Recently, knockdown of TOX3 was reported
to cause upregulation of BRCA1 in MCF-7 cells [44], thus
implicating TOX3 as a BRCA1 repressor. In contrast, we
observed upregulation of BRCA1 and BRCA2 (along with
other genes related by network analysis) upon TOX3 ex-
pression, consistent with our observation that TOX3 pri-
marily acts as a transcriptional activator. The reason for
this apparent discrepancy is unclear, although our experi-
ments were carried out under estrogen-depleted condi-
tions, which might alter BRCA1 regulation.
We also noted significant overlap between genes
whose expression was altered by TOX3 and genes regu-
lated by estrogen in MCF-7 cells [31]. This may reflect
the direct action of TOX3 on estrogen responsive ele-
ments [17]. Given that we performed our microarray
analysis under estrogen-depleted conditions, this sug-
gests that TOX3 can regulate a subset of estrogen re-
sponsive genes in a ligand-independent manner. Indeed,
this was demonstrated for the well-characterized ER
target gene TFF1, which was induced by TOX3 under
estrogen-depleted conditions and in MDA-MB-231 fol-
lowing co-transfection of TOX3 and ER. While the exact
mechanism of action of TOX3 remains to be elucidated,
TOX3 was able to induce TFF1 eRNAs even in the ab-
sence of estrogen, possibly indicative of promotion of a
similar looping mechanism to that of ER and its ligand.
Moreover, although we could not extinguish TFF1 ex-
pression in TOX3-expressing MCF7 by inhibition of ER,
ER and TOX3 together were sufficient to induce TFF1
expression in MDA-MB-231 cells in the absence of estro-
gen. Thus, the relationship of ER and TOX3 in the ab-
sence of estrogen may be complex, as these data suggest
that TOX3-mediated induction but not maintenance of
TFF1 gene expression is ER-dependent. Alternatively,
other cofactors that differ between MCF7 and MDA-
MB-231 cells may complicate the interpretation of these
results. Nevertheless, unliganded ER has recently been
shown to play a significant role in gene regulation in
breast cancer cells [48], and we would propose that TOX3
plays a modulatory role on this activity.
Additionally, we observed hyper-responsive TFF1 gene
expression following estrogen treatment in cells overex-
pressing TOX3. Expression of TOX3 may be involved in
the resistance to endocrine therapy reported to occur in
some LumB cancers [41]. Consistent with this, cells
overexpressing TOX3 were better able to survive under
estrogen-deprived conditions.Conclusions
Together, our data suggest that TOX3 expression within
the context of breast cancer is likely a tumor promoter
rather than a strict tumor suppressor as had been pro-
posed based on the decrease in TOX3 expression asso-
ciated with disease risk [11]. In addition, TOX3 has the
potential to regulate ER target gene expression in the
face of limiting concentrations of estrogen, of potential
importance in considering therapeutic modalities for
TOX3+ breast cancer. One key issue to be resolved is
how a decrease in TOX3 expression alters the mammary
gland. BRCA1 mutation carriers have an accumulation
of ER− luminal progenitors, the presumed cell of origin
for triple negative tumors [49-52]. One possibility is that
individuals carrying the TOX3 disease-risk allele simi-
larly have an accumulation of a cell population that is
more susceptible to tumorigenesis. Given our findings that
TOX3 is expressed in luminal progenitors and that family
member TOX regulates cell differentiation [7,8,53], lower
TOX3 expression may alter the equilibrium of luminal cell
populations in favor of a progenitor state that is more sus-
ceptible to tumorigenesis. This might also explain the as-
sociation of the TOX3 risk allele with triple negative
breast cancer [54,55]. However, once cell transformation
is initiated, TOX3 likely plays a significant role in rende-
ring resulting tumors more aggressive and metastatic, and
thus may serve as a novel biomarker for LumB breast
cancer.
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